TR BioSurgical Completes Comparative Orthopedic Study In Dogs With Ligament Injuries

Main Category: Veterinary
Article Date: 22 Oct 2008 - 10:00 PDT

email to a friend   printer friendly   view / write opinions   rate article

TR BioSurgical, LLC, announced the completion of a study in dogs undergoing surgery for cranial cruciate ligament (CCL) repair, a market estimated to exceed $1 billion in annual dog owner spending in the United States. The study compared the use of TR Matrix™, an osteopromotive bioscaffold, to autologous cancellous bone graft for osteotomy repair associated with the Tibial Tuberosity Advancement (TTA) surgery, a common procedure for cranial cruciate ligament (CCL) injury. Results indicate TR Matrix™ is equal or superior to autologous bone grafting in clinical and radiographic scoring and may be a viable alternative to bone grafting procedures.

Dr. Jeff Kellerman, VP of R&D, stated, "The ultimate goals of cranial cruciate ligament repair in dogs are rapid recovery time and a return to near normal structure and function. In order for the TPLO and TTA procedures to achieve these goals they require cutting of healthy bone in the patient, referred to as an osteotomy. Application of TR Matrix is a critical step in achieving rapid and unimpaired healing of these osteotomy sites thereby accomplishing key goals in cruciate ligament repair and surgical outcome."

About Cranial Cruciate Ligament (CCL) Injury in Dogs

CCL injury is a prevalent injury in dogs and is similar to the anterior cruciate ligament (ACL) injury in humans. The injury results in joint instability and often accelerates the process of degenerative joint disease.

About TR Matrix

TR Matrix is designed for two of the most common surgical procedures to repair the cranial cruciate ligament, namely the Tibial Plateau Leveling Osteotomy (TPLO) and Tibial Tuberosity Advancement (TTA). TR Matrix, considered a medical device, is a lyophilized bioscaffold with a unique, open polar configuration that results in physiological tissue repair. Cells binding to TR Matrix have been shown to increase production tissue repair factors, including bone morphogenic protein-2 (BMP-2), connective tissue growth factor (CTGF), transforming growth factor beta 1 & 3 (TGF β1 & TGF β3), aggrecan, and other factors.

About TR BioSurgical, LLC

TR BioSurgical is a privately held veterinary company developing a range of biomaterials and devices for tissue repair and regenerative medicine. TR BioSurgical has specific interests in ophthalmology, dermatology, and orthopedics including cartilage repair. Please visit http://www.trbio.com for more information.

Source
Jeff Kellerman DVM, MBA
http://www.trbio.com